Ken Griffin Cardiol Therapeutics Inc. Transaction History
Citadel Advisors LLC
- $618 Billion
- Q3 2025
A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Cardiol Therapeutics Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 463,462 shares of CRDL stock, worth $472,731. This represents 0.0% of its overall portfolio holdings.
Number of Shares
463,462
Previous 37,600
1132.61%
Holding current value
$472,731
Previous $51,000
845.1%
% of portfolio
0.0%
Previous 0.0%
Shares
8 transactions
Others Institutions Holding CRDL
# of Institutions
52Shares Held
7.39MCall Options Held
25KPut Options Held
0-
Tejara Capital LTD London, X02.63MShares$2.68 Million1.47% of portfolio
-
Advisor Shares Investments LLC Bethesda, MD557KShares$568,5350.11% of portfolio
-
Bank Of America Corp Charlotte, NC551KShares$562,0740.0% of portfolio
-
Marshall Wace, LLP London, X0544KShares$555,2030.0% of portfolio
-
Goldman Sachs Group Inc New York, NY322KShares$328,2360.0% of portfolio
About Cardiol Therapeutics Inc.
- Ticker CRDL
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 61,942,500
- Market Cap $63.2M
- Description
- Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of cardiovascular disease (CVD). Its lead product is CardiolRx, which is in Phase II/III multi-national, randomized, double-blind, and placebo-controlled study to evaluate t...